ベンチャー探訪　Alnylam社の創業者が参画するCity社、日本発技術取り入れ次世代のsiRNA創薬 | AN Venture Partners

ベンチャー探訪　Alnylam社の創業者が参画するCity社、日本発技術取り入れ次世代のsiRNA創薬

MediaPortfolio Companies

ベンチャー探訪　Alnylam社の創業者が参画するCity社、日本発技術取り入れ次世代のsiRNA創薬

January 17, 2025

Crystalys Therapeutics Advances Phase 3 Trials of Dotinurad for the Treatment of Gout with Dosing of First Patient

Press Release

Portfolio Companies

Crystalys Therapeutics Advances Phase 3 Trials of Dotinurad for the Treatment of Gout with Dosing of First Patient

San Diego, October 21, 2025

AN Venture Partner’s New Portfolio Company, Crystalys Therapeutics Launches with $205M Series A Financing to Advance Next-Generation Gout Treatment

Press Release

Portfolio Companies

AN Venture Partner’s New Portfolio Company, Crystalys Therapeutics Launches with $205M Series A Financing to Advance Next-Generation Gout Treatment

San Diego, September 30, 2025

Privacy Policy

This website uses Google Analytics cookies for access analysis only. The collected data is used solely for improving the website and is handled appropriately. By clicking "AGREE", you consent to the use of cookies.

Privacy Policy

This website uses Google Analytics cookies for access analysis only. The collected data is used solely for improving the website and is handled appropriately. By clicking "AGREE", you consent to the use of cookies.